Posted from IHUB, but I included the results as we
Post# of 30067
Posted On: 06/09/2014 11:06:45 AM
Posted from IHUB, but I included the results as well:
Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
WO 2013188210 A2
Insert-tag-herewww.google.com/patents/WO2013188210A2?cl=en
Results
[0122] Statistical analyses demonstrated that eltoprazine administered to Parkinson's disease patients with levodopa-induced dyskinesia (LID), statistically significantly reduced LID at both the 5 mg dose (p = 0.0007) and the 7.5 mg dose (p = 0.0467), as compared to placebo, when measured by the CDRS scale (see Fig. 1). In addition, eltoprazine administration at these doses did not affect L-DOPA efficacy , as measured by the UPDRS score (see Fig. 2); both the 5 mg and 7.5 mg doses were statistically significant as compared to placebo). At the 5 mg dose, eltoprazine reduced LID in PD patients statistically significantly - as measured by the Rush Scale AUC.
[0123] Furthermore, eltoprazine was well tolerated in this study, as there were no serious adverse events.
Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
WO 2013188210 A2
Insert-tag-herewww.google.com/patents/WO2013188210A2?cl=en
Results
[0122] Statistical analyses demonstrated that eltoprazine administered to Parkinson's disease patients with levodopa-induced dyskinesia (LID), statistically significantly reduced LID at both the 5 mg dose (p = 0.0007) and the 7.5 mg dose (p = 0.0467), as compared to placebo, when measured by the CDRS scale (see Fig. 1). In addition, eltoprazine administration at these doses did not affect L-DOPA efficacy , as measured by the UPDRS score (see Fig. 2); both the 5 mg and 7.5 mg doses were statistically significant as compared to placebo). At the 5 mg dose, eltoprazine reduced LID in PD patients statistically significantly - as measured by the Rush Scale AUC.
[0123] Furthermore, eltoprazine was well tolerated in this study, as there were no serious adverse events.
(0)
(0)